Companies covered: Novo Nordisk A/S (NYSE:NVO), Eli Lilly and Company (NYSE:LLY), Amgen Inc. (NASDAQ:AMGN), Merck & Company, Inc. (NYSE:MRK), Roche Holdings Ltd. (ADR) (OTCMKTS:RHHBY), Moderna (NASDAQ:MRNA), BioNTech SE (ADR) (NASDAQ:BNTX), Bristol-Myers Squibb Company (NYSE:BMY), Novartis AG (NYSE:NVS), Cabaletta Bio Inc. (NASDAQ:CABA), Kyverna Therapeutics Inc. (NASDAQ:KYTX), Pfizer, Inc. (NYSE:PFE), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), AbbVie Inc. (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Altimmune Inc. (NASDAQ:ALT), Aerovate Therapeutics Inc. (NASDAQ:AVTE), Madrigal Pharmaceuticals (NASDAQ:MDGL), Akero Therapeutics Inc. (NASDAQ:AKRO), 89bio Inc. (NASDAQ:ETNB), Insmed, Inc. (NASDAQ:INSM), Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Intellia Therapeutics Inc. (NASDAQ:NTLA), CRISPR Therapeutics AG (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), Immunome Inc. (NASDAQ:IMNM), Disc Medicine Inc. (NASDAQ:IRON), Apogee Therapeutics Inc. (NASDAQ:APGE), ORIC Pharmaceuticals Inc. (NASDAQ:ORIC), TScan Therapeutics Inc. (NASDAQ:TCRX), Nuvalent Inc. (NASDAQ:NUVL), Inozyme Pharma Inc. (NASDAQ:INZY), Beam Therapeutics Inc. (NASDAQ:BEAM), Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), Scholar Rock Holding Corp. (NASDAQ:SRRK), y-mAbs Therapeutics Inc. (NASDAQ:YMAB), Abivax SA (NASDAQ:ABVX), BioVie Inc. (NASDAQ:BIVI), Equillium Inc. (NASDAQ:EQ), Organovo Holdings, Inc. (NASDAQ:ONVO), PDS Biotechnology Corporation (NASDAQ:PDSB)
